Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α‐synuclein, tau, amyloid‐β or vascular pathology-Reference-Cited by-同舟云学术

Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α‐synuclein, tau, amyloid‐β or vascular pathology

Published:2021-05-19 Issue:7 Volume:47 Page:1080-1091
ISSN:0305-1846
Container-title:Neuropathology and Applied Neurobiology
language:en
Short-container-title:Neuropathol Appl Neurobiol

Author:

Pablo‐Fernández Eduardo¹²^ORCID,Courtney Robert¹,Rockliffe Alice¹,Gentleman Steve³^ORCID,Holton Janice L.¹,Warner Thomas T.¹²

Affiliation:

1. Queen Square Brain Bank for Neurological Disorders Department of Clinical and Movement Neurosciences UCL Queen Square Institute of Neurology London UK

2. Department of Clinical and Movement Neurosciences Reta Lila Weston Institute of Neurological Studies UCL Queen Square Institute of Neurology London UK

3. Neuropathology Unit Department of Brain Sciences Imperial College London London UK

Publisher

Wiley

Subject

Physiology (medical),Neurology (clinical),Neurology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nan.12728

Reference55 articles.

1. Neuroendocrine abnormalities in Parkinson's disease

2. Insulin in the Brain: Sources, Localization and Functions

3. The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

4. Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?

5. Association between diabetes and subsequent Parkinson disease

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?;Neurology;2024-08-27

2. Untargeted serum metabolic profiling of diabetes mellitus among Parkinson’s disease patients;npj Parkinson's Disease;2024-05-10

3. The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology;International Journal of Molecular Sciences;2024-04-15

4. GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression;2024-02-28

5. Cognitive Benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu;Current Medicinal Chemistry;2024-01